Clinical Trials Logo

Filter by:
NCT ID: NCT01023581 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes

AM7D
Start date: November 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of alogliptin combined with metformin, once daily (QD) or twice daily (BID), in participants with Type 2 Diabetes.

NCT ID: NCT01020448 Completed - Prostate Cancer Clinical Trials

Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer

Triptocare
Start date: November 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effect of an initial hormonal treatment gonadotrophin-releasing hormone (GnRH Agonist) on 2 biomarkers (PCA3 and TMPRSS2-ERG), in patients with histologically confirmed and advanced stages of prostate cancer. Their characteristics, according to risk factors such as PSA and Gleason score will be determined at baseline and 1, 3 and 6 month post-treatment.

NCT ID: NCT01020123 Completed - Clinical trials for Type II Diabetes Mellitus

Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients

Start date: October 2009
Phase: Phase 2
Study type: Interventional

The primary aim is to evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in TD2M Patients

NCT ID: NCT01018173 Completed - Clinical trials for Diabetes Mellitus Type 2

A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease

Start date: January 2010
Phase: Phase 3
Study type: Interventional

This randomized, double-blind, placebo-controlled parallel arm study will assess efficacy and safety and the effects of taspoglutide on cardiovascular events in patients with inadequately controlled type 2 diabetes mellitus and established cardiovascular disease. Patients will be randomized to receive either taspoglutide subcutaneously (sc) 10mg weekly for 4 weeks followed by 20mg sc weekly, or weekly sc placebo, in addition to background anti-hyperglycemic medication and standard of care treatment for cardiovascular disease. Anticipated time on study treatment is up to 2 years. Target sample size is 2000 patients.

NCT ID: NCT01015287 Completed - Clinical trials for Acute Coronary Syndromes

A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction

ACCOAST
Start date: December 2009
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to investigate the potential benefits/risks regarding pretreatment with prasugrel in non-ST-elevation myocardial infarction (NSTEMI) participants with elevated troponin scheduled for coronary angiography/percutaneous coronary intervention (PCI).

NCT ID: NCT01013675 Completed - Influenza Vaccines Clinical Trials

Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Elderly

Start date: November 2009
Phase: Phase 2
Study type: Interventional

A controlled, double-blind study to determine the immunogenicity and safety of influenza cell derived vaccine in elderly subjects.

NCT ID: NCT01009086 Completed - Clinical trials for Arthritis, Psoriatic

A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis

Start date: December 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effectiveness (improvement of signs and symptoms) and safety of ustekinumab in participants with active psoriatic arthritis.

NCT ID: NCT01001377 Completed - Clinical trials for Metastatic Colorectal Cancer

ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Start date: February 2, 2010
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to compare the effect of panitumumab versus cetuximab on overall survival (OS) for chemorefractory metastatic colorectal cancer (mCRC) among patients with wild-type Kirsten rat Sarcoma-2 virus (KRAS) tumors.

NCT ID: NCT00997061 Completed - Clinical trials for Lung Cancer, Small Cell

SCOT Registry: Small Cell Lung Cancer Treatment and Outcome

SCOT
Start date: November 2009
Phase: N/A
Study type: Observational

The registry is an international, multicenter, observational registry of newly diagnosed patients with SCLC. Data will be entered into an electronic CRF (eCRF) via Internet access. Treatment plan remains the responsibility of the patient's physician and data collected in this registry will reflect a "real world" approach of the diagnosis and treatment of patients with SCLC. Approximately 60 centres in 13 countries will take part in this registry. It is expected that about 500 patients will be recruited during a period of 6 to 9 months according to the feasibility.

NCT ID: NCT00989131 Completed - Clinical trials for Fallopian Tube Cancer

Study of Paclitaxel in Patients With Ovarian Cancer

Start date: February 2009
Phase: Phase 3
Study type: Interventional

RATIONALE: Paclitaxel is one of the most widely used human anticancer agents. Paclitaxel has a low degree of solubility and Cremophor EL is typically used as the solubiliser. Cremophor EL is known to cause hypersensitivity reactions that can be life-threatening. As Paclical® does not contain Cremophor EL, hypersensitivity reactions can be expected to be less. PURPOSE: To study the efficay and safety of two different formulations of paclitaxel, Paclical® and Taxol®.